Literature DB >> 28379029

Molecular genetic background of an autosomal dominant hypercholesterolemia in the Czech Republic.

L Tichý1, L Fajkusová, P Zapletalová, L Schwarzová, M Vrablík, T Freiberger.   

Abstract

Autosomal dominant hypercholesterolemia (ADH), more known as familial hypercholesterolemia (FH), is a lipid metabolism disorder characterized by an elevation in low-density lipoprotein cholesterol (LDL-C) and increased risk for cardiovascular disease. In this study, we assessed a spectrum of mutations causing ADH in 3914 unrelated Czech patients with clinical diagnosis of hypercholesterolemia. Samples have been collected within the framework of the MedPed project running in the Czech Republic since 1998. So far we have found 432 patients (11.0 %) with the APOB gene mutation p.(Arg3527Gln) and 864 patients (22.1 %) with the LDLR gene mutation. In 864 probands carrying the LDLR gene mutation, 182 unique allelic variants were detected. We have identified 14 patients homozygous for mutations in the LDLR or APOB genes. We performed function analyses of p.(Leu15Pro) and p.(Gly20Arg) sequence variations.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28379029     DOI: 10.33549/physiolres.933587

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  2 in total

1.  Molecular Characterization of Familial Hypercholesterolemia in a North American Cohort.

Authors:  Abhimanyu Garg; Sergio Fazio; P Barton Duell; Alexis Baass; Chandrasekhar Udata; Tenshang Joh; Tom Riel; Marina Sirota; Danielle Dettling; Hong Liang; Pamela D Garzone; Barry Gumbiner; Hong Wan
Journal:  J Endocr Soc       Date:  2019-11-29

2.  Molecular Genetic Approach and Evaluation of Cardiovascular Events in Patients with Clinical Familial Hypercholesterolemia Phenotype from Romania.

Authors:  Cristiana-Elena Vlad; Liliana Georgeta Foia; Roxana Popescu; Ioana Popa; Ruxandra Aanicai; Delia Reurean-Pintilei; Vasilica Toma; Laura Florea; Mehmet Kanbay; Adrian Covic
Journal:  J Clin Med       Date:  2021-03-31       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.